Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Multicenter, Observational Study on Erbitux® (Cetuximab) in Patients With EGFR-expressing, KRAS Wild-type Metastatic Colorectal Cancer

NCT01074333 is registered in ClinicalTrials.gov with Merck KGaA, Darmstadt, Germany as lead sponsor.

NCT NCT01074333
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01074333 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Multicenter, Observational Study on Erbitux® (Cetuximab) in Patients With EGFR-expressing, KRAS Wild-type Metastatic Colorectal Cancer
Lead sponsor
Merck KGaA, Darmstadt, Germany
Phase
Observational
Overall status
Terminated
Start date
September 30, 2008
Completion date
January 31, 2012
Enrollment
146 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal neoplasm